[ANEMIA IN CHRONIC KIDNEY DISEASE]

Area of Science:

• Nephrology
• Hematology
• Primary Care Medicine

Background:

• Renal anemia is a common complication of chronic kidney disease (CKD), increasing with disease severity.
• Effective management of renal anemia is crucial for patient outcomes and quality of life.

Purpose of the Study:

• To update family physicians on current approaches to renal anemia management in CKD.
• To provide guidance aligned with national guidelines for primary healthcare providers.

Main Methods:

• Systematic literature search of PubMed and Cochrane databases (1996-2015).
• Keywords included: anemia, chronic renal failure, erythropoietin, primary health care.
• Manual search of relevant articles and textbooks.

Main Results:

• Erythropoiesis-stimulating agents (ESA) can slow CKD progression, decrease transfusion needs, and enhance patient quality of life.
• Recommended target hemoglobin (Hb) is 110-120 g/L, with higher levels linked to increased mortality and cardiovascular events in dialysis patients.
• Individualized Hb targets are essential, considering CKD stage, age, and patient-specific factors.

Conclusions:

• Early detection and treatment of anemia in CKD patients using ESA are critically important.
• Systematic prevention strategies and adherence to national guidelines by family practitioners can optimize CKD patient care.
• Personalized treatment approaches are key to managing renal anemia effectively.